• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ii蛋白被蛋白酶解为p25。

Proteolytic cleavage of Ii to p25.

作者信息

Thomas L J, Nguyen Q V, Elliott W L, Humphreys R E

机构信息

Department of Pharmacology, University of Massachusetts Medical School, Worcester 01655.

出版信息

J Immunol. 1988 Apr 15;140(8):2670-4.

PMID:3282009
Abstract

The 25,000-Da protein that is seen in immunoprecipitates with antibodies to class II MHC molecules or to Ii was shown to be a C-terminal fragment of Ii. [35S]Methionine pulse-chase labeling of polyclonally activated B lymphocytes or lymphoblastoid cell lines demonstrated maximal appearance of p25 in Percoll-separated endosomal fractions at 20- to 40-min chase times (studies in progress). This finding was consistent with the view that proteolysis of Ii to p25 and its release might catalyze the binding of digested foreign peptides to class II molecules and/or govern release of such charged complexes to traffic to the cell surface. We examined the structural relationship of p25 to Ii and the basis for cleavage of a relatively restricted site just external to the transmembranal segment. [35S]Methionine-labeled Ii and associated molecules were immunoprecipitated with a mAb to native Ii and then denatured, resolubilized, and subjected to a second immunoprecipitation with various antibodies. Two antisera to C-terminal peptides of Ii (183 to 193 and 192 to 211), but not antibodies to an N-terminal peptide (12 to 28), did immunoprecipitate p25. The three antibodies to C-terminal and N-terminal peptides all immunoprecipitated denatured Ii proteins. The mAb to Ii immunoprecipitated [35S]methionine-labeled p25 but not [35S]cysteine-labeled p25. This finding was consistent with loss of a portion of Ii containing the only cysteine in Ii, Cys28. Digestion of class II MHC Ag-Ii complexes with various proteases yielded proteins migrating at and near p25 in two-dimensional electrophoretic gels. Upon increasing the duration of protease digestion, the 25,000-Da fragments were relatively resistant to further digestion. This observation was consistent with the presence of secondary structures (domains) leaving a relatively protease-sensitive (Ig hinge-like) region in Ii near its insertion into the membrane.

摘要

用针对II类MHC分子或Ii的抗体进行免疫沉淀时所见到的25,000道尔顿蛋白,被证明是Ii的C末端片段。对多克隆激活的B淋巴细胞或淋巴母细胞系进行[35S]甲硫氨酸脉冲追踪标记显示,在20至40分钟的追踪时间内,Percoll分离的内体部分中p25出现最多(研究正在进行中)。这一发现与以下观点一致,即Ii蛋白水解为p25及其释放可能催化消化后的外源肽与II类分子的结合和/或控制此类带电复合物释放到细胞表面。我们研究了p25与Ii的结构关系以及跨膜段外部相对受限位点的切割基础。用针对天然Ii的单克隆抗体对[35S]甲硫氨酸标记的Ii及相关分子进行免疫沉淀,然后使其变性、再溶解,并用各种抗体进行第二次免疫沉淀。两种针对Ii C末端肽(183至193和192至211)的抗血清能免疫沉淀p25,但针对N末端肽(12至28)的抗体则不能。三种针对C末端和N末端肽的抗体都能免疫沉淀变性的Ii蛋白。针对Ii的单克隆抗体能免疫沉淀[35S]甲硫氨酸标记的p25,但不能免疫沉淀[35S]半胱氨酸标记的p25。这一发现与Ii中唯一的半胱氨酸Cys28所在的一部分Ii丢失一致。用各种蛋白酶消化II类MHC Ag-Ii复合物,在二维电泳凝胶中产生迁移至p25及其附近的蛋白。随着蛋白酶消化时间的延长,25,000道尔顿的片段对进一步消化相对有抗性。这一观察结果与Ii中存在二级结构(结构域)一致,该结构在Ii插入膜的附近留下一个相对蛋白酶敏感(类似Ig铰链区)的区域。

相似文献

1
Proteolytic cleavage of Ii to p25.Ii蛋白被蛋白酶解为p25。
J Immunol. 1988 Apr 15;140(8):2670-4.
2
Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.在B淋巴母细胞中,新生的MHC II类分子-恒定链复合物向溶酶体区室的转运以及恒定链被半胱氨酸蛋白酶的蛋白水解作用先于肽结合。
J Immunol. 1995 Jan 1;154(1):137-50.
3
Kinetics of Ii synthesis, processing, and turnover in n-butyrate-treated Burkitt's lymphoma cell lines which express or do not express class II antigens and in hairy leukemic cells.在表达或不表达II类抗原的丁酸盐处理的伯基特淋巴瘤细胞系以及毛细胞白血病细胞中Ii合成、加工和周转的动力学。
J Immunol. 1985 May;134(5):3539-49.
4
Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.通过形成一个C末端25 kDa恒定链片段,DR分子从与恒定链的复合物中释放出来。
Mol Immunol. 1993 Dec;30(18):1623-32. doi: 10.1016/0161-5890(93)90435-e.
5
Invariant chain associates with HLA class II antigens via its extracytoplasmic region.恒定链通过其胞外区域与II类组织相容性复合体抗原结合。
J Immunol. 1986 Apr 1;136(7):2519-25.
6
Structural analysis of invariant chain subsets as a function of their association with MHC class II chains.
Arch Biochem Biophys. 1995 Feb 20;317(1):128-32. doi: 10.1006/abbi.1995.1144.
7
Murine Ia-associated invariant chain's processing to complex oligosaccharide forms and its dissociation from the I-Ak complex.
J Immunol. 1985 Jul;135(1):399-407.
8
A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.一种在抗原呈递方面存在缺陷的突变抗原呈递细胞表达构象改变的II类主要组织相容性复合体分子。
J Immunol. 1993 May 15;150(10):4206-17.
9
Characterization of fragments of the murine Ia-associated invariant chain.
J Immunol. 1991 Feb 1;146(3):920-7.
10
Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.HLA-DM表达的变化影响正常B细胞系中MHC II类αβ:II类相关恒定链肽复合物向成熟的肽结合II类αβ二聚体的转化。
J Immunol. 1996 Mar 15;156(6):2196 - 2204.

引用本文的文献

1
A role for NADPH oxidase in antigen presentation.NADPH氧化酶在抗原呈递中的作用。
Front Immunol. 2013 Sep 23;4:295. doi: 10.3389/fimmu.2013.00295.
2
Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules.HLA-DR和HLA-DP分子中α链与β链配对的结构要求。
J Exp Med. 1990 Mar 1;171(3):615-28. doi: 10.1084/jem.171.3.615.
3
Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules.II类相关恒定链的蛋白水解作用在细胞内HLA - DR分子中产生一个肽结合位点。
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3150-4. doi: 10.1073/pnas.88.8.3150.
4
Intracellular transport and localization of major histocompatibility complex class II molecules and associated invariant chain.主要组织相容性复合体II类分子及相关恒定链的细胞内运输与定位
J Cell Biol. 1991 Dec;115(5):1213-23. doi: 10.1083/jcb.115.5.1213.